 <h1>Totect Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>dexrazoxane</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about dexrazoxane. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Totect.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dexrazoxane: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dexrazoxane (the active ingredient contained in Totect) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking dexrazoxane:</p><p>
<i>More common</i>
</p><ul>
<li>Bluish color</li>
<li>changes in skin color</li>
<li>chest pain</li>
<li>chills</li>
<li>cold hands and feet</li>
<li>cough</li>
<li>difficult or labored breathing</li>
<li>fever</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>sneezing</li>
<li>sore throat</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>tenderness</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest discomfort</li>
<li>fast, irregular, or pounding heartbeat</li>
<li>pain at the injection site</li>
<li>ulcers, sores, or white spots in the mouth</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dexrazoxane may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>discouragement</li>
<li>dizziness</li>
<li>feeling sad or empty</li>
<li>hair loss</li>
<li>headache</li>
<li>irritability</li>
<li>lack or loss of appetite</li>
<li>loss of interest or pleasure</li>
<li>muscle pain, spasms, cramps, or stiffness</li>
<li>nausea</li>
<li>stomach pain</li>
<li>thinning of the hair</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dexrazoxane: intravenous powder for injection</i></p><h3>General</h3><p>Adverse events reported are from clinical trials where patients were also receiving chemotherapy while on this drug, and reflect the combination of this drug, already administered chemotherapy, and the patients underlying condition.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (77%), vomiting (59%), stomatitis (34%), diarrhea (21%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, constipation, esophagitis, dysphagia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased white blood count (73%), decreased neutrophils (61%) decreased hemoglobin (43%), decreased platelets (23%)</p>
<p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (up to 100%)</p>
<p><b>Common</b> (1% to 10%): Streaking/erythema, urticaria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain/discomfort (16%)</p>
<p><b>Common</b> (1% to 10%): Injection site phlebitis, extravasation<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (28%), increased ALT (22%)</p>
<p><b>Common</b> (1% to 10%): Increased LDH, increased alkaline phosphatase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Neurotoxicity (17%), dizziness (11%)</p>
<p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (42%)</p>
<p><b>Common</b> (1% to 10%): Increased calcium total, decreased sodium<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (23%), sepsis (17%), postoperative infection (16%)</p>
<p><b>Common</b> (1% to 10%): Pneumonia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (34%), fatigue (61%), pain on injection (13%), edema peripheral (10%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (14%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiac disorders, phlebitis, hemorrhage<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, cough<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Totect (dexrazoxane)." Cumberland Pharmaceuticals Inc, Nashville, TN. </p><p id="ref_2">2. "Product Information. Zinecard (dexrazoxane)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Totect (dexrazoxane)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Totect &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Zinecard</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Extravasation</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dexrazoxane: intravenous powder for injection</i></p><h3>General</h3><p>Adverse events reported are from clinical trials where patients were also receiving chemotherapy while on this drug, and reflect the combination of this drug, already administered chemotherapy, and the patients underlying condition.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (77%), vomiting (59%), stomatitis (34%), diarrhea (21%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, constipation, esophagitis, dysphagia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased white blood count (73%), decreased neutrophils (61%) decreased hemoglobin (43%), decreased platelets (23%)</p><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (up to 100%)</p><p><b>Common</b> (1% to 10%): Streaking/erythema, urticaria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain/discomfort (16%)</p><p><b>Common</b> (1% to 10%): Injection site phlebitis, extravasation<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (28%), increased ALT (22%)</p><p><b>Common</b> (1% to 10%): Increased LDH, increased alkaline phosphatase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Neurotoxicity (17%), dizziness (11%)</p><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (42%)</p><p><b>Common</b> (1% to 10%): Increased calcium total, decreased sodium<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (23%), sepsis (17%), postoperative infection (16%)</p><p><b>Common</b> (1% to 10%): Pneumonia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (34%), fatigue (61%), pain on injection (13%), edema peripheral (10%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (14%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiac disorders, phlebitis, hemorrhage<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, cough<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Totect (dexrazoxane)." Cumberland Pharmaceuticals Inc, Nashville, TN. </p><p id="ref_2">2. "Product Information. Zinecard (dexrazoxane)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2>More about Totect (dexrazoxane)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Totect &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Extravasation</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>